Most Recent
A former QRx Pharma director's prediction that shareholders would not receive "anything of consequence" from a class action settlement has proven true, with only a small slice of the $7 million settlement expected to go to shareholders.
A BP worker whose employment was reinstated after he was unfairly dismissed for sharing a video clip that included subtitles placed over a scene from the movie 'Downfall' about Adolf Hitler, has been awarded $201,000 in lost wages and superannuation.
In airing a ‘7:30' segment that revealed racehorses were being slaughtered in violation of industry rules, the ABC acted with malice in what was a "set up" designed to make the head of Racing NSW "look bad", a court has heard.
Insurance policies that may be worth up to $46 million and have derailed settlement approval in two class actions against sandalwood producer Quintis were "cobbled together" and contained errors and omissions, a court has heard.
Two competing shareholder class actions against global winemaker and distributor Treasury Wine Estates over an earnings downgrade in January this year should be consolidated, and a judge should pick just one law firm to run the case, a court has heard.
The corporate regulator will not take former AMP chair Catherine Brenner to court after investigating her conduct as part of probes that are expected to lead to at least five cases against the wealth management firm before the end of the year.
The company that makes Wicked Sister desserts has suffered a defeat in its trade mark battle against the maker of Wicked dipping sauces, with a judge removing some of its trade marks from the register.
AMP, Commonwealth Bank and Westpac are facing potential class actions over commissions grandfathered by the FoFA reforms and the firms alleged failure to protect client interests.
Communications and technical services company BSA Limited has slammed as "opportunistic" an employment class action by allegedly underpaid technicians, saying the media was informed of the proceedings before it was.
ASX-listed generic drug maker Mayne Pharma is facing a possible shareholder class action over disclosures related to US price-fixing allegations against the ASX-listed company.